Research Article: Impact of sequential (first- to third-generation) EGFR-TKI treatment on corrected QT interval in NSCLC patients
Introduction:
Objective: To evaluate the impact of sequential (first- to third-generation) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment on top-corrected QT interval (top-QTc) in non-small cell lung cancer (NSCLC) patients.
Read more